Protection of intracellular dopamine cytotoxicity by dopamine disposition and metabolism factors

Journal of Neurochemistry

Volumn 77, Issue 3, 2001, Pages 776-785

  Weingarten, Paul ^a   Zhou, Qun Yong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytotoxicity; Dopamine; Glutathione S transferase; Macrophage migration inhibitory factor; Monoamine oxidase; Vesicular monoamine transporter

Indexed keywords

1,4 BENZOQUINONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DNA FRAGMENT; DOPAMINE; GLUTATHIONE TRANSFERASE; LEVODOPA; MACROPHAGE MIGRATION INHIBITION FACTOR; MELANIN;

ANIMAL CELL; ARTICLE; CELL STRAIN; CHO CELL; CONTROLLED STUDY; DOPAMINE METABOLISM; FIBROBLAST CULTURE; GENE OVEREXPRESSION; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; CHO CELLS; CRICETINAE; DNA FRAGMENTATION; DOPAMINE; GENE EXPRESSION; GLUTATHIONE TRANSFERASE; LEVODOPA; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MELANINS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MONOAMINE OXIDASE; NEUROPEPTIDES; OXIDATION-REDUCTION; TRANSFECTION; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

ANIMALIA;

EID: 0035017743     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2001.00263.x     Document Type: Article

References (74)

1. Abell C. W. (1987) Monoamine oxidase A and B from human liver and brain. Methods Enzymol. 142, 638-650.
2. Alagarsamy S., Phillips M., Pappas T. and Johnson K. M. (1997) Dopamine neurotoxicity in cortical neurons. Drug Alcohol Depend. 48, 105-111.
3. Baez S., Segura-Aguilar J., Widersten M., Johansson A. S. and Mannervik B. (1997) Glutathione transferases catalyse the detoxification of oxidized metabolites (0-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem. J. 324, 25-28.
4. Basma A. N., Morris E. J., Nicklas W. J. and Geller H. M. (1995) L-DOPA cytotoxicity to PC12 cells in culture is via its autooxidation. J. Neurochem. 64, 825-832.
5. Benedetti M. S. and Tipton K. F. (1998) Monoamine oxidases and related amine oxidases as phase I enzymes in the metabolism of xenobiotics. J. Neural. Transm. 52 (Suppl.), 149-171.
6. Ben-Shachar D., Zuk R. and Glinka Y. (1995) Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem. 64, 718-723.
7. Bertrand F., Atfi A., Cadoret A., L'Allemain G., Robin H., Lascols O., Capeau J. and Cherqui G. (1998) A role for nuclear factor κB in the antiapoptotic function of insulin. J. Biol Chem. 273, 2931-2938.
8. Boulton A. A., Yu P. H. and Tipton K. F. (1988) Biogenic amine adducts, monoamine oxidase inhibitors, and smoking. Lancet 1, 114-115.
9. Brown J. M., Hanson G. R. and Fleckenstein A. E. (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J. Neurochem. 74, 2221-2223.
10. Cadet J. L. and Brannock C. (1998) Free radicals and the pathobiology of brain DA systems. Neurochem. Int. 32, 117-131.
11. Calne D. B. (1992) The free radical hypothesis in idiopathic parkinsonism: evidence against it. Ann. Neurol. 32, 799-803.
12. Charteris A. and John R. (1975) An investigation of the assay of dopamine using trinitrobenzenesulphonic acid. Anal. Biochem. 66, 365-371.
13. Chiueh C. C., Huang S. J. and Murphy D. L. (1994) Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity. J. Neural Transm. 41 (Suppl.), 189-196.
14. Cohen G. (1986) Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Adv. Neurol. 45, 119-125.
15. Dexter D. T., Carter C. J., Wells F. R., Javoy-Agid F. J., Agid Y., Lees A., Jenner P. and Marsden C. D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389.
16. Drukarch B. and van Muiswinkel F. L. (2000) Drug treatment of Parkinson's disease. Time for phase II. Biochem. Pharmacol. 59, 1023-1031.
17. Duffy S., So A. and Murphy T. H. (1998) Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage. J. Neurochem. 71, 69-77.
18. Fon E. A., Pothos E. N., Sun B. C., Killeen N., Sulzer D. and Edwards R. H. (1997) Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19, 1271-1283.
19. Glinka Y., Gassen M. and Youdim M. B. H. (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J. Neural Transm. 50 (Suppl.), 55-66.
20. Graham D. G., Tiffany S. M., Bell W. R. and Gutknecht W. F. (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644-653.
21. Habig W. H. P., Abstract M. J. and Jakoby W. B. (1974) Glutathione S-transferases: the first enzymatic step in mercapturic acid formation. J. Biol. Chem. 249, 7130-7139.
22. Hansen M. B., Nielsen S. E. and Berg K. (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119, 203-210.
23. Hastings T. G. (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64, 919-924.
24. Hastings T. G. and Zigmond M. J. (1997) Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. J. Neural. Transm. 49 (Suppl), 103-110.
25. He N. G., Singhal S. S., Srivastava S. K., Zimniak P., Awasthi Y. C. and Awasthi S. (1996) Transfection of a 4-hydroxynonenal metabolizing glutathione S-transferase isozyme, mouse GSTA4-4, confers doxorubicin resistance to Chinese hamster ovary cells. Arch. Biochem. Biophys. 333, 214-220.
26. Hertzman C., Wiens M., Bowering D., Snow B. and Caine D. (1990) Parkinson's disease: a case-control study of occupational and environmental risk factors. Am. J. Ind. Med. 17, 349-355.
27. Hirsch E., Graybiel A. M. and Agid Y. A. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348.
28. + -induced toxicity: comparison between MN9D cells and CHO cells. Toxicol. Lett. 104, 49-56.
29. Jacobsson S. O. P. and Fowler C. J. (1999) Dopamine and glutamate neurotoxicity in cultured chick telencephali cells: effects of NMDA antagonists, antioxidants and MAO inhibitors. Neurochem. Int. 34, 49-62.
30. Kastner A., Hirsch E. C., Lejeune O., Javoy-Agid F., Rascol O. and Agid Y. (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem. 59, 1080-1089.
31. Kogan F. J., Nichols W. K. and Gibb J. W. (1976) Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur. J. Pharmacol. 36, 363-371.
32. Lai C. T. and Yu P. (1997a) Dopamine and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-DOPA)-induced cytotoxicily towards catecholaminergic neuroblastoma SH-SY5Y cells. Biochem. Pharmacol. 53, 363-372.
33. Lai C. T. and Yu P. (1997b) R(-)-deprenyl potentiates dopamine-induced cytotoxicity toard catecholaminergic neuroblastoma SH-SY5Y cells. Toxicol. Appl. Pharmacol. 142, 186-191.
34. Langston J. W., Ballard P. A., Tetrud I. W. and Irwin I. (1983) Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 219, 979-980.
35. Lees A. J. and The Parkinson's Disease Research Group UK (1995) Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br. Med. J. 311, 1602-1607.
36. Liu Y. and Edwards R. H. (1997) The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20, 125-156.
37. + toxicity encodes a vesicular amine transporter. Cell 70, 539-551.
38. 11C]WIN-35,428. J. Neurosci. 18, 8417-8422.
39. McNaught K. S. P., Carrupt P. A., Altomare C., Cellamare S., Carotti A., Testa B., Jenner P. and Marsden C. D. (1998) Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem. Pharmacol. 56, 921-933.
40. Masserano J. M., Gong L., Kulaga H., Baker I. and Wyatt R. J. (1996) Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol. Pharmacol. 50, 1309-1315.
41. Matsubara K., Gonda T., Sawada H., Uezono T, Kobayashi Y., Kawamura T., Ohtaki K., Kimura K. and Akaike A. (1998) Endogenously occurring -carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson's disease. J. Neurochem. 70, 727-735.
42. Matsunaga J., Sinha D., Pannell L., Santis C., Solano F., Wistow G. J. and Hearing V. J. (1999) Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. J. Biol. Chem. 274, 3268-3271.
43. Mena I., Marin O., Fuenzalida S. and Cotzias G. (1967) Chronic manganese poisoning. Clinical picture and manganese turnover. Neurology 17, 128-136.
44. Mercuri N. B., Scarponi M., Bonci A., Siniscalchi A. and Bernardi G. (1997) Monoamine oxidase inhibition causes a long-term prolongation of the dopaminergic-induced response in rat midbrain dopaminergic cells. J. Neurosci. 17, 2267-2272.
45. Miller G. W., Gainetdinov R. R., Levey A. I. and Caron M. G. (1999) Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 20, 424-429.
46. Montine T. J., Picklo M. J., Amarnath V., Whetsell W. O. and Graham D. G. (1997) Neurotoxicity of endogenous cysteinylcatechols. Exp. Neurol. 148, 26-33.
47. Mytilineou C., Han S. and Cohen G. (1993) Toxic and protective effects of L-Dopa on mesencephalic cell cultures. J. Neurochem. 61, 1470-1478.
48. Nishibori M., Nakaya N., Tahara A., Kawabata M., Mori S. and Saeki K. (1996) Presence of macrophage migration inhibitory factor (MIF) in ependyma, astrocytes and neurons in the bovine brain. Neurosci. Lett. 213, 193-196.
49. Offen D., Ziv J., Gorodin S., Barzilai A., Malik Z. and Melamed E. (1995) Dopamine-induced programmed cell death in mouse thymocytes. Biochim. Biophys. Acta 1268, 171-177.
50. Ogawa N. (1995) Possible neuroprotective therapy for Parkinson's disease. Acta Med. Okayama 49, 179-185.
51. Olanow C. W. and Tatton W. G. (1999) Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123-144.
52. Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann. Neurol. 39, 29-36.
53. Przedborski S. and Jackson-Lewis V. (1998) Mechanisms of MPTP toxicity. Mov. Disord. 13, 35-38.
54. Richards J. G., Saura J., Luque J. M., Cesura A. M., Gottowick J., Malherbe P., Borroni E. and Gray J. (1998) Monoamine oxidases: from brain maps to physiology and transgenics to pathophysiology. J. Neural Transm. 52 (Suppl.), 173-187.
55. Salonen T., Haapalinna A., Heinonen E., Suhonen J. and Hervonen A. (1996) Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity. Acta Neuropathol. 91, 466-474.
56. Schneider E. (1995) DATATOP-Study: significance of its results in the treatment of Parkinson's disease. J. Neural Transm. 46 (Suppl.), 391-397.
57. Schuldiner S., Liu Y. and Edwards R. H. (1993) Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. J. Biol. Chem. 268, 29-34.
58. Schuldiner S., Shirvan A. and Linial M. (1995) Vesicular neurotransmitter transporters: from bacteria to humans. Physiol. Rev. 75, 369-392.
59. Segura-Aguilar J., Baez S., Widersten M., Welch C. and Mannervik B. (1997) Human class mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxification of the dopamine metabolite aminochrome. J. Biol. Chem. 272, 5727-5731.
60. Shin J. C., Chen K. and Ridd M. J. (1999) Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 22, 197-217.
61. Shoulson I. and The Parkinson Study Group (1998) DATATOP: a decade of neuroprotective inquiry. Ann. Neurol. 44, S160-S166.
62. Sonsalla P. K., Nicklas W. J. and Heikkila R. E. (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243, 398-400.
63. Swope M. D. and Lolis E. (1999) Macrophage migration inhibitory factor: cytokine, hormone, or enzyme? Rev. Physiol. Biochem. Pharmacol. 139, 1-32.
64. Uhl G. R. (1998) Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann. Neurol. 43, 555-560.
65. Walkinshaw G. and Waters C. M. (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. J. Clin. Invest. 95, 2458-2464.
66. Wang Y. M., Gainetdinov R. R., Fumagalli F., Xu F., Jones S. R., Bock C. B., Miller G. W., Wightman R. M. and Caron M. G. (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19, 1285-1296.
67. Wei Q., Yeung M., Jurma O. P. and Andersen J. K. (1996) Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP. J. Neurosci. Res. 46, 666-673.
68. Wei Q., Jurma O. P. and Andersen J. K. (1997) Increased expression of monoamine oxidase-B results in enhanced neurite degeneration in methamphetamine-treated PC12 cells. J. Neurosci. Res. 50, 618-626.
69. Weingarten P., Bermak J. and Zhou Q.-Y. (2001) Evidence for non-oxidative dopamine cytotoxicity: potent activation of NF-kappa B and lack of protection by anti-oxidants. J. Neurochem. in press.
70. Weiser W. Y., Temple P. A., Witek-Giannotti J. S., Remold H. G., Clark S. C. and David J. R. (1989) Molecular cloning of a cDNAencoding a human macrophage migration inhibitory factor. Proc. Natl Acad. Sci. USA 86, 7522-7526.
71. Wilkinson J. and Clapper M. L. (1997) Detoxification enzymes and chemoprevention. Proc. Soc. Exp. Biol. Med. 216, 192-200.
72. Willis G. L. and Armstrong S. M. (1998) Orphan neurones and amine excess: the functional neuropathology of parkinsonism and neuropsychiatric disease. Brain Res. Rev. 27, 177-242.
73. Wyllie A. H. (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284, 555-556.
74. Yamada T., McGeer P. L., Baimbridge K. G. and McGeer E. G. (1990) Relative sparing in Parkinson's disease of substantia nigra DA neurons containing calbindin-D28K. Brain Res. 526, 303-307.